Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) is a dual-target (DPP-4 and SGLT2) fixed-dose combination preparation developed by Mitsubishi Tanabe Pharma (Japan). It demonstrates synergistic efficacy advantages in the treatment of type 2 diabetes.
How to Purchase Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)
Overseas Purchase
Patients may choose to consult and purchase the medication at hospital pharmacies or licensed drugstores in countries/regions where Teneligliptin Hydrobromide/Canagliflozin Combination Tablets have been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase via Medical Service Institutions
Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and offer professional consultation and guidance.
Precautions for Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)
Baseline Assessment Before Medication Use
Dynamic monitoring of renal function: Estimated Glomerular Filtration Rate (eGFR) must be measured before starting medication. Rechecks should be conducted at Week 4 and Week 12 after initiating treatment; if eGFR remains below 45 mL/min/1.73m², discontinue the medication.
Cardiovascular risk screening: A baseline electrocardiogram (ECG) is required to assess the QT interval, especially in patients co-administered with antiarrhythmic drugs.
Infection marker screening: Conduct urine routine tests and reproductive system examinations.
Emergency Response for Adverse Reactions
Management of hypoglycemia: Prepare glucose preparations and educate patients to recognize prodromal symptoms such as palpitations and sweating.
Warning for diabetic ketoacidosis (DKA): Even if random blood glucose is <13.9 mmol/L, if symptoms such as abdominal pain or nausea occur, immediately test blood ketone levels.
Prevention and control of urinary tract infections: It is recommended to drink more than 2000 mL of water daily and pay attention to perineal hygiene.
Management of Drug Interactions
When co-administered with sulfonylureas, the original dose of sulfonylureas should be reduced by 25%-50%.
When co-administered with loop diuretics, monitor orthostatic blood pressure.
Use with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) with caution.
Authentication of Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) (Genuine vs. Counterfeit)
Verification of Official Markings
Packaging characteristics: The original drug box should be accompanied by a Japanese instruction manual, and the batch number should follow the format of "numbers + letters".
Tablet appearance: Light orange film-coated tablets with a diameter of 8.6 mm and a thickness of 4.5 mm; no cracks or discoloration on the surface.
Verification of Physical Properties
Dissolution test: When the tablet is placed in warm water, it should completely disintegrate within 30 minutes.
Weight testing: The weight of a single tablet is 244 mg; any deviation exceeding ±5% is considered suspicious.
Monitoring of Clinical Responses
Fasting blood glucose should decrease by ≥1 mmol/L within 1 week.
Mild gastrointestinal reactions are common.
If there is no expected therapeutic effect or abnormal symptoms occur, send the medication for inspection immediately.
